Download PDF
Thromb Haemost 2020; 120(05): 866-875
DOI: 10.1055/s-0040-1709711
Atherosclerosis and Ischaemic Disease
Georg Thieme Verlag KG Stuttgart · New York

Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis

Daniele Pastori   *
1   Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Italy
,
Alessio Farcomeni   *
2   Department of Economics and Finance, University of Rome “Tor Vergata”, Rome, Italy
,
Alberto Milanese
3   Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
,
Francesco Del Sole
1   Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Italy
,
Danilo Menichelli
1   Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Italy
,
William R. Hiatt   **
4   Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States
5   Division of Cardiology and CPC Clinical Research, University of Colorado School of Medicine, Aurora, Colorado, United States
,
Francesco Violi   **
1   Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Italy
› Author Affiliations Funding None.
Further Information

Publication History

10 December 2019

05 March 2020

Publication Date:
05 May 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Background Statins are guidelines recommended in patients with peripheral artery disease (PAD) for the prevention of cardiovascular (CV) events. Comprehensive meta-data on the impact of statins on major adverse limb events (MALE) in PAD patients are lacking. We examined the association of statin use with MALE in patients with PAD.

Methods We performed a systematic review (registered at PROSPERO: number CRD42019137111) and metanalysis of studies retrieved from PubMed (via MEDLINE) and Cochrane (CENTRAL) databases addressing the impact of statin on MALE including amputation and graft occlusion/revascularization. Secondary endpoints were all-cause death, composite CV endpoints, CV death, and stroke.

Results We included 51 studies with 138,060 PAD patients, of whom 48,459 (35.1%) were treated with statins. The analysis included 2 randomized controlled trials, 20 prospective, and 29 retrospective studies. Overall, 11,396 MALE events, 21,624 deaths, 4,852 composite CV endpoints, 4,609 CV deaths, and 860 strokes were used for the analysis. Statins reduced MALE incidence by 30% (pooled hazard ratio [HR]: 0.702; 95% confidence interval [CI]: 0.605–0.815) and amputations by 35% (HR: 0.654; 95% CI: 0.522–0.819), all-cause mortality by 39% (pooled HR: 0.608, 95% CI: 0.543–0.680), CV death by 41% (HR: 0.594; 95% CI: 0.455–0.777), composite CV endpoints by 34% (pooled HR: 0.662; 95% CI: 0.591–0.741) and ischemic stroke by 28% (pooled HR: 0.718; 95% CI: 0.620–0.831).

Conclusion Statins reduce the incidence of MALE, all-cause, and CV mortality in patients with PAD. In PAD, a high proportion of MALE events and deaths could be prevented by implementing a statin prescription in this patient population.

Keywords

statin - peripheral artery disease - major adverse limb event - stroke - amputation - cardiovascular death - all-cause death

* Equal contribution.


** Joint senior authorship.


Supplementary Material

 

  • References

  • 1 Fowkes FG, Rudan D, Rudan I. , et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382 (9901): 1329-1340
    CrossrefPubMedGoogle Scholar
  • 2 Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol 2017; 14 (03) 156-170
    CrossrefPubMedGoogle Scholar
  • 3 Aboyans V, Ricco JB, Bartelink MEL. , et al; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39 (09) 763-816
    CrossrefPubMedGoogle Scholar
  • 4 Violi F, Loffredo L, Carnevale R, Pignatelli P, Pastori D. Atherothrombosis and oxidative stress: mechanisms and management in elderly. Antioxid Redox Signal 2017; 27 (14) 1083-1124
    CrossrefPubMedGoogle Scholar
  • 5 Anand SS, Caron F, Eikelboom JW. , et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol 2018; 71 (20) 2306-2315
    CrossrefPubMedGoogle Scholar
  • 6 Jones WS, Patel MR. Antithrombotic therapy in peripheral artery disease: generating and translating evidence into practice. J Am Coll Cardiol 2018; 71 (03) 352-362
    CrossrefPubMedGoogle Scholar
  • 7 Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018; 15 (12) 757-769
    CrossrefPubMedGoogle Scholar
  • 8 McBride CL, Akeroyd JM, Ramsey DJ. , et al. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: insights from the department of veterans affairs. Vasc Med 2018; 23 (03) 232-240
    CrossrefPubMedGoogle Scholar
  • 9 Hess CN, Huang Z, Patel MR. , et al. Acute limb ischemia in peripheral artery disease: insights from EUCLID. Circulation 2019
    PubMedGoogle Scholar
  • 10 Ramos R, García-Gil M, Comas-Cufí M. , et al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll Cardiol 2016; 67 (06) 630-640
    PubMedGoogle Scholar
  • 11 Antoniou GA, Hajibandeh S, Hajibandeh S, Vallabhaneni SR, Brennan JA, Torella F. Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. J Vasc Surg 2015; 61 (02) 519-532.e1
    CrossrefPubMedGoogle Scholar
  • 12 Gerhard-Herman MD, Gornik HL, Barrett C. , et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2017; 135 (12) e726-e779
    PubMedGoogle Scholar
  • 13 Wells GA, Shea B, O'Connell D. , et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed March 23, 2020
    PubMedGoogle Scholar
  • 14 Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16
    CrossrefPubMedGoogle Scholar
  • 15 Miyata T, Higashi Y, Shigematsu H. , et al. Evaluation of risk factors for limb-specific peripheral vascular events in patients with peripheral artery disease: a post hoc analysis of the SEASON prospective observational study. Angiology 2019; 70 (06) 506-514
    CrossrefPubMedGoogle Scholar
  • 16 Spoden M, Nimptsch U, Mansky T. Amputation rates of the lower limb by amputation level - observational study using German national hospital discharge data from 2005 to 2015. BMC Health Serv Res 2019; 19 (01) 8
    CrossrefPubMedGoogle Scholar
  • 17 Malyar NM, Freisinger E, Meyborg M. , et al. Low rates of revascularization and high in-hospital mortality in patients with ischemic lower limb amputation: morbidity and mortality of ischemic amputation. Angiology 2016; 67 (09) 860-869
    CrossrefPubMedGoogle Scholar
  • 18 Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA 2016; 316 (19) 2008-2024
    CrossrefPubMedGoogle Scholar
  • 19 Kolls BJ, Sapp S, Rockhold FW. , et al. Stroke in patients with peripheral artery disease. Stroke 2019; 50 (06) 1356-1363
    CrossrefPubMedGoogle Scholar
  • 20 Nastasi DR, Smith JR, Moxon JV, Trollope A, Golledge J. Prescription of pharmacotherapy and the incidence of stroke in patients with symptoms of peripheral artery disease. Stroke 2018; 49 (12) 2953-2960
    CrossrefPubMedGoogle Scholar
  • 21 DeCarlo C, Scher L, Shariff S, Phair J, Lipsitz E, Garg K. Statin use and other factors associated with mortality after major lower extremity amputation. J Vasc Surg 2017; 66 (01) 216-225
    CrossrefPubMedGoogle Scholar
  • 22 Berger A, Simpson A, Bhagnani T. , et al. Incidence and cost of major adverse cardiovascular events and major adverse limb events in patients with chronic coronary artery disease or peripheral artery disease. Am J Cardiol 2019; 123 (12) 1893-1899
    CrossrefPubMedGoogle Scholar
  • 23 Anand SS, Bosch J, Eikelboom JW. , et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017
    PubMedGoogle Scholar
  • 24 Pastori D, Eikelboom JW, Anand SS. , et al. Management of patients with asymptomatic and symptomatic carotid artery disease: update on anti-thrombotic therapy. Thromb Haemost 2019; 119 (04) 576-585
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Bonaca MP, Nault P, Giugliano RP. , et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 Inhibition in subjects with elevated risk). Circulation 2018; 137 (04) 338-350
    CrossrefPubMedGoogle Scholar
  • 26 Bonaca MP, Gutierrez JA, Creager MA. , et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2°P-TIMI 50). Circulation 2016; 133 (10) 997-1005
    CrossrefPubMedGoogle Scholar
  • 27 Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 90 (07) 789-791
    CrossrefPubMedGoogle Scholar
  • 28 Mohler III ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108 (12) 1481-1486
    CrossrefPubMedGoogle Scholar
  • 29 Abbruzzese TA, Havens J, Belkin M. , et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004; 39 (06) 1178-1185
    CrossrefPubMedGoogle Scholar
  • 30 Schillinger M, Exner M, Mlekusch W. , et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004; 25 (09) 742-748
    CrossrefPubMedGoogle Scholar
  • 31 Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45 (04) 645-654
    CrossrefPubMedGoogle Scholar
  • 32 Kumbhani DJ, Steg PG, Cannon CP. , et al; REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014; 35 (41) 2864-2872
    CrossrefPubMedGoogle Scholar
  • 33 Westin GG, Armstrong EJ, Bang H. , et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014; 63 (07) 682-690
    CrossrefPubMedGoogle Scholar
  • 34 Dosluoglu HH, Davari-Farid S, Pourafkari L, Harris LM, Nader ND. Statin use is associated with improved overall survival without affecting patency and limb salvage rates following open or endovascular revascularization. Vasc Med 2014; 19 (02) 86-93
    CrossrefPubMedGoogle Scholar
  • 35 Ward RP, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol 2005; 104 (03) 264-268
    CrossrefPubMedGoogle Scholar
  • 36 de Liefde II, Hoeks SE, van Gestel YR. , et al. Usefulness of hypertensive blood pressure response during a single-stage exercise test to predict long-term outcome in patients with peripheral arterial disease. Am J Cardiol 2008; 102 (07) 921-926
    CrossrefPubMedGoogle Scholar
  • 37 Jones WS, Patel MR, Tsai TT. , et al. Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. Am Heart J 2015; 170 (02) 400-408
    CrossrefPubMedGoogle Scholar
  • 38 Vrsalović M, Vučur K, Car B, Krčmar T, Vrsalović Presečki A. C-reactive protein, renal function, and cardiovascular outcome in patients with symptomatic peripheral artery disease and preserved left ventricular systolic function. Croat Med J 2015; 56 (04) 351-356
    CrossrefPubMedGoogle Scholar
  • 39 Lee JH, Ko YG, Shin DH. , et al. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. J Vasc Surg 2016; 63 (03) 756-763
    CrossrefPubMedGoogle Scholar
  • 40 Matsubara Y, Matsumoto T, Inoue K. , et al. Sarcopenia is a risk factor for cardiovascular events experienced by patients with critical limb ischemia. J Vasc Surg 2017; 65 (05) 1390-1397
    CrossrefPubMedGoogle Scholar
  • 41 Siracuse JJ, Van Orden K, Kalish JA. , et al; Vascular Quality Initiative. Endovascular treatment of the common femoral artery in the vascular quality initiative. J Vasc Surg 2017; 65 (04) 1039-1046
    CrossrefPubMedGoogle Scholar
  • 42 Kumakura H, Kanai H, Matsuo Y, Iwasaki T, Ichikawa S. Asymptomatic cerebral infarction is a predictor of long-term survival and vascular or limb events in peripheral arterial disease. Eur Heart J Qual Care Clin Outcomes 2019; 5 (01) 43-50
    CrossrefPubMedGoogle Scholar
  • 43 Khan SZ, Rivero M, Nader ND. , et al. Metformin is associated with improved survival and decreased cardiac events with no impact on patency and limb salvage after revascularization for peripheral arterial disease. Ann Vasc Surg 2019; 55: 63-77
    CrossrefPubMedGoogle Scholar
  • 44 Feringa HH, Karagiannis SE, van Waning VH. , et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 2007; 45 (05) 936-943
    CrossrefPubMedGoogle Scholar
  • 45 Feringa HH, Karagiannis SE, Vidakovic R. , et al. Glycemic control, lipid-lowering treatment, and prognosis in diabetic patients with peripheral atherosclerotic disease. Ann Vasc Surg 2007; 21 (06) 780-789
    CrossrefPubMedGoogle Scholar
  • 46 Vidula H, Tian L, Liu K. , et al. Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels. Am J Cardiol 2010; 105 (09) 1348-1352
    CrossrefPubMedGoogle Scholar
  • 47 Tomoi Y, Soga Y, Iida O. , et al. Efficacy of statin treatment after endovascular therapy for isolated below-the-knee disease in patients with critical limb ischemia. Cardiovasc Interv Ther 2013; 28 (04) 374-382
    CrossrefPubMedGoogle Scholar
  • 48 Hsu CY, Chen YT, Su YW, Chang CC, Huang PH, Lin SJ. Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab 2017; 102 (07) 2373-2381
    CrossrefPubMedGoogle Scholar
  • 49 Pasqualini L, Schillaci G, Pirro M. , et al. Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease. J Intern Med 2007; 262 (06) 668-677
    CrossrefPubMedGoogle Scholar
  • 50 Suckow BD, Kraiss LW, Schanzer A. , et al; Vascular Study Group of New England. Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg 2015; 61 (01) 126-133
    CrossrefPubMedGoogle Scholar
  • 51 Tern PJW, Kujawiak I, Saha P, Berrett TB, Chowdhury MM, Coughlin PA. Site and burden of lower limb atherosclerosis predicts long-term mortality in a cohort of patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2018; 56 (06) 849-856
    CrossrefPubMedGoogle Scholar
  • 52 O'Donnell TFX, Deery SE, Darling JD. , et al. Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia. J Vasc Surg 2017; 66 (02) 572-578
    CrossrefPubMedGoogle Scholar
  • 53 Iida O, Nakamura M, Yamauchi Y. , et al; OLIVE Investigators. 3-year outcomes of the olive registry, a prospective multicenter study of patients with critical limb ischemia: a prospective, multi-center, three-year follow-up study on endovascular treatment for infra-inguinal vessel in patients with critical limb ischemia. JACC Cardiovasc Interv 2015; 8 (11) 1493-1502
    CrossrefPubMedGoogle Scholar
  • 54 Isma N, Barani J, Mattiasson I, Lindblad B, Gottsäter A. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology 2008; 59 (05) 542-548
    CrossrefPubMedGoogle Scholar
  • 55 Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008; 47 (04) 774-781
    CrossrefPubMedGoogle Scholar
  • 56 Aiello FA, Khan AA, Meltzer AJ, Gallagher KA, McKinsey JF, Schneider DB. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg 2012; 55 (02) 371-379
    CrossrefPubMedGoogle Scholar
  • 57 Faglia E, Clerici G, Scatena A. , et al. Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: an observational study. Diabetes Res Clin Pract 2014; 103 (02) 292-297
    CrossrefPubMedGoogle Scholar
  • 58 Parmar GM, Novak Z, Spangler E. , et al. Statin use improves limb salvage after intervention for peripheral arterial disease. J Vasc Surg 2019; 70 (02) 539-546
    CrossrefPubMedGoogle Scholar
  • 59 Henke PK, Blackburn S, Proctor MC. , et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 2004; 39 (02) 357-365
    CrossrefPubMedGoogle Scholar
  • 60 Carter A, Murphy MO, Halka AT. , et al. The natural history of stenoses within lower limb arterial bypass grafts using a graft surveillance program. Ann Vasc Surg 2007; 21 (06) 695-703
    CrossrefPubMedGoogle Scholar
  • 61 Stavroulakis K, Borowski M, Torsello G, Bisdas T. ; CRITISCH collaborators. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg 2017; 66 (05) 1534-1542
    CrossrefPubMedGoogle Scholar
  • 62 Thatipelli MR, Pellikka PA, McBane RD. , et al. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. J Vasc Surg 2007; 46 (01) 62-70 , discussion 70 discussion
    CrossrefPubMedGoogle Scholar
  • 63 van Gestel YR, Hoeks SE, Sin DD. , et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008; 102 (02) 192-196
    CrossrefPubMedGoogle Scholar
  • 64 Randon C, Jacobs B, De Ryck F, Beele H, Vermassen F. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg 2010; 51 (04) 869-877
    CrossrefPubMedGoogle Scholar
  • 65 Scali ST, Beck AW, Nolan BW. , et al. Completion duplex ultrasound predicts early graft thrombosis after crural bypass in patients with critical limb ischemia. J Vasc Surg 2011; 54 (04) 1006-1010
    CrossrefPubMedGoogle Scholar
  • 66 Iida O, Soga Y, Kawasaki D. , et al. Angiographic restenosis and its clinical impact after infrapopliteal angioplasty. Eur J Vasc Endovasc Surg 2012; 44 (04) 425-431
    CrossrefPubMedGoogle Scholar
  • 67 Siracuse JJ, Giles KA, Pomposelli FB. , et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg 2012; 55 (04) 1001-1007
    CrossrefPubMedGoogle Scholar
  • 68 Baril DT, Patel VI, Judelson DR. , et al; Vascular Study Group of New England. Outcomes of lower extremity bypass performed for acute limb ischemia. J Vasc Surg 2013; 58 (04) 949-956
    CrossrefPubMedGoogle Scholar
  • 69 Saqib NU, Domenick N, Cho JS. , et al. Predictors and outcomes of restenosis following tibial artery endovascular interventions for critical limb ischemia. J Vasc Surg 2013; 57 (03) 692-699
    CrossrefPubMedGoogle Scholar
  • 70 Vogel TR, Dombrovskiy VY, Galiñanes EL, Kruse RL. Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv 2013; 6 (06) 694-700
    CrossrefPubMedGoogle Scholar
  • 71 Todoran TM, Connors G, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay S. Femoral artery percutaneous revascularization for patients with critical limb ischemia: outcomes compared to patients with claudication over 2.5 years. Vasc Med 2012; 17 (03) 138-144
    CrossrefPubMedGoogle Scholar
  • 72 Siracuse JJ, Gill HL, Cassidy SP. , et al. Endovascular treatment of lesions in the below-knee popliteal artery. J Vasc Surg 2014; 60 (02) 356-361
    CrossrefPubMedGoogle Scholar
  • 73 Spiliopoulos S, Theodosiadou V, Katsanos K. , et al. Long-term clinical outcomes of infrapopliteal drug-eluting stent placement for critical limb ischemia in diabetic patients. J Vasc Interv Radiol 2015; 26 (10) 1423-1430
    CrossrefPubMedGoogle Scholar
  • 74 Kim W, Gandhi RT, Peña CS. , et al. The influence of statin therapy on restenosis in patients who underwent nitinol stent implantation for de novo femoropopliteal artery disease: two-year follow-up at a single center. J Vasc Interv Radiol 2016; 27 (10) 1494-1501
    CrossrefPubMedGoogle Scholar
  • 75 Klingelhoefer E, Bergert H, Kersting S. , et al. Predictive factors for better bypass patency and limb salvage after prosthetic above-knee bypass reconstruction. J Vasc Surg 2016; 64 (02) 380-388
    CrossrefPubMedGoogle Scholar
  • 76 Mehaffey JH, Hawkins RB, Fashandi A. , et al. Lower extremity bypass for critical limb ischemia decreases major adverse limb events with equivalent cardiac risk compared with endovascular intervention. J Vasc Surg 2017; 66 (04) 1109-1116.e1
    CrossrefPubMedGoogle Scholar
  • 77 de Grijs D, Teixeira P, Katz S. The association of statin therapy with the primary patency of femoral and popliteal artery stents. J Vasc Surg 2018; 67 (05) 1472-1479
    CrossrefPubMedGoogle Scholar